Ritz Carlton Hotel
1150 22nd Street, NW
Washington, DC 20037
Monday, August 29
1:00 – 1:15 p.m. Welcome and Opening Remarks
Amy Gutmann, Ph.D.
Commission Chair
James Wagner, Ph.D.
Commission Vice-Chair
1:15 – 2:00 p.m. Session 1: Historical Investigation – Research Details
Commission Members
2:00 – 3:00 p.m. Session 2: Historical Investigation – Ethics Standards and Practices
Commission Members
3:00 – 3:15 p.m. Conclusions on the Ethics of the Experiments
Amy Gutmann, Ph.D.
James Wagner, Ph.D.
Tuesday, August 30
9:00 – 9:15 a.m. Opening Remarks
Amy Gutmann, Ph.D.
James Wagner, Ph.D.
9:15 – 9:45 a.m. Session 3: Human Subjects Protection Reform
Ezekiel J. Emanuel, M.D., Ph.D.
Former Chief, Clinical Center Department of Bioethics
National Institutes of Health
9:45 – 10:30 a.m. Session 4: International Research Panel Results and Discussion
Nelson Michael, M.D., Ph.D.
Commission Member
Christine Grady, R.N., Ph.D.
Commission Member
10:30 – 10:45 a.m. Break
10:45 – 11:45 a.m. Session 5: Community Engagement – Needs, Models and U.S. Actions
Carletta Tilousi
Member, Havasupai Tribal Council
Havasupai Tribe
Mitchell Warren
Executive Director, AVAC: Global Advocacy for HIV Prevention
Roger I. Glass, M.D., Ph.D.
Director, Fogarty International Center
Associate Director for International Research
National Institutes of Health
11:45 a.m. – 12:15 p.m. Session 6: Staff Report on Current Scientific Studies Supported by the Federal Government
Jeremy Sugarman, M.D., M.P.H., M.A.
Senior Advisor
Michelle Groman, J.D.
Senior Policy & Research Analyst
12:15 – 1:15 p.m. Lunch Break
1:15 – 2:00 p.m. Session 7: Trial Design and International Standards
Ruth Macklin, Ph.D.
Professor of Bioethics, Department of Epidemiology and Population Health
Albert Einstein College of Medicine
Robert Temple, M.D.
Deputy Center Director for Clinical Science
Center for Drug Evaluation and Research
Acting Director, Office of Drug Evaluation I
U.S. Food and Drug Administration (FDA)
2:00 – 2:15 p.m. Concluding Remarks
Amy Gutmann, Ph.D.
James Wagner, Ph.D.
